REPORT FROM THE AMERICAN EPILEPSY SOCIETY 65TH ANNUAL MEETING, BALTIMORE, MD, DECEMBER 2-6, 2011 – Perampanel (E2007) is a selective AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid)-type glutamate receptor antagonist that is currently in late-phase development for the treatment of refractory partial-onset seizures.